Proniras Corp

SEATTLE, WA · Founded 2016 · Biotech · Private

Novel pharmacological treatment for opiate withdrawal

Claim this profile

Follows are private to you and power your alerts

Updated · proniras.com

Sector
Biotech
Headquarters
SEATTLE, WA
Founded
2016
Latest Form D
$4.6M, Dec 2023
Total capital
$11.1M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$7.4M
2 Form D · last Dec 2023
34 months since last filing
Federal contracts
$3.7M
1 award · Health and Human S
Rank in Biotech#100 of 4373
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

2017201820192020202120222023FEDERAL ↑EQUITY ↓Cumulative $11.1M$3.7M1st Form D$2.8M2nd Form D$4.6M
2017201920212023FEDERAL ↑EQUITY ↓Cumulative $11.1M$3.7M1st Form D$2.8M2nd Form D$4.6M

Latest events

  • Private capital raisedForm D · SEC · 2nd filing$4.6M
  • Federal contractHealth and Human S · Proniras Corporation$3.7M
  • Private capital raisedForm D · SEC · 1st filing$2.8M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Asish XavierDirectorNamed in SEC Form D filings
  • ATUL SARANDirectorNamed in SEC Form D filings
  • CHRISTOPHER TOOMBSExecutive OfficerNamed in SEC Form D filings
  • David Johnston SchubertExecutive Officer, PromoterNamed in SEC Form D filings
  • Joel Johnston MarcusDirectorNamed in SEC Form D filings
  • Lindsay Johnston RayleExecutive Officer, PromoterNamed in SEC Form D filings
Show all 10 people
  • M. Johnston ErwinDirectorNamed in SEC Form D filings
  • Steve Johnston GillisExecutive Officer, PromoterNamed in SEC Form D filings
  • STEVEN GILLISDirectorNamed in SEC Form D filings
  • THONG LEExecutive Officer, Director, PromoterNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • CELDARA MEDICAL, LLCSimilar federal contract value in Biotech · $4M in contracts
  • BioQ Pharma IncSimilar federal contract value in Biotech · $4M in contracts
  • ANTAGEN BIOSCIENCES INCSimilar federal contract value in Biotech · $3.7M in contracts
  • Helix, Inc.Similar federal contract value in Biotech · $3.6M in contracts
  • ABVACC, INC.Similar federal contract value in Biotech · $3.5M in contracts
  • DNASTAR, INC.Similar federal contract value in Biotech · $3.4M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .